1.	Phase III Randomized Study of Cisplatin With or Without Monoclonal Antibody C225 in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5397, E5397, NCT00003809
2.	Phase III Randomized Study of Radiotherapy With or Without Concurrent Cetuximab in Patients With Advanced Squamous Cell Carcinoma of the Oropharynx, Hypopharynx, or Larynx Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UAB-9901, IMCL-CP02-9815, NCI-G99-1657, NCT00004227
3.	Phase III Randomized Study of Gemcitabine With Versus Without Cetuximab as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: NCI Protocol IDs: SWOG-S0205, S0205, NCT00075686, CALGB-S0205, CAN-NCIC-PAC1, PAC1
4.	Phase III Randomized Study of Fluorouracil and Leucovorin Calcium With Irinotecan or Oxaliplatin and With or Without Cetuximab in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-80203, NCT00077233
5.	Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA225006, NCT00063141
6.	Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA225014, NCT00061815
7.	Phase III Randomized Study of Cetuximab and Best Supportive Care Versus Best Supportive Care Alone in Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 16 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-CO17, AGITG-CAN-NCIC-CO17, BMS-CA225-025, IMCL-CAN-NCIC-CO17, NCT00079066, CO17
8.	Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA225-099, NCT00112294
9.	Phase III Randomized Study of Continuous Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil (OxMdG) or Oxaliplatin and Capecitabine (XELOX) With Versus Without Cetuximab Versus Intermittent Combination Chemotherapy With OxMdG or XELOX as First-Line Therapy in Patients with Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UKM-MRC-COIN-CR10, EU-20516, NCT00182715, EUDRACT-2004-002951-16, ISRCTN27286448, COIN
10.	Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 62202-002, NCT00122460
11.	FLOX in Combination With Cetuximab in First-Line Treatment of Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 74 Sponsor: Other Protocol IDs: Nordic VII, EudraCT no.: 2005-000117-34, NCT00145314
12.	Study of Cisplatin/Vinorelbine +/- Cetuximab as First-Line Treatment of Advanced Non Small Cell Lung Cancer(FLEX) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 62202-046, NCT00148798
13.	Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CAIRO2, NCT00208546
14.	Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 62202-013, NCT00154102
15.	Trial of Cetuximab, Bevacizumab and 5FU/Leucovorin Versus Oxaliplatin, Bevacizumab and 5FU/Leucovorin in Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CA225251, NCT00252564
16.	Phase III Randomized Study of Concurrent Accelerated Fractionated Radiotherapy and Cisplatin With Versus Without Cetuximab in Patients With Stage III or IV Squamous Cell Carcinoma of the Oropharynx, Hypopharynx, or Larynx Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0522, RTOG 0522, NCT00265941
17.	Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986
18.	Phase III Randomized Study of Irinotecan Hydrochloride-Based Chemotherapy and Cetuximab With Versus Without Bevacizumab in Patients With Metastatic Colorectal Cancer That Progressed on First-Line Therapy (Treatment Arm III Closed to Accrual as of 4/20/2009) Phase: Phase III Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0600, S0600, CALGB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600, NCT00499369
19.	Phase IB/IIA Study of Chimeric MOAB C225 for Advanced Solid Tumors (Summary Last Modified 01/96) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to physiologic 70 Sponsor: Other Protocol IDs: YALE-HIC-8192, YALE-01254, NCI-V95-0723
20.	Phase IB/IIA Study of MOAB C225 plus Doxorubicin in Androgen-Independent Prostate Cancer (Summary Last Modified 12/98) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: MSKCC-95092, NCI-V96-0833
21.	Phase I/II Study of Cetuximab, Gemcitabine, and Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UAB-9909, IMCL-CP02-9925, UAB-F010524006, NCI-G01-2030, NCT00027755
22.	Phase I/II Study of Sorafenib, Cetuximab, and Irinotecan in Patients With Advanced or Metastatic Colorectal Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J04104, JHOC-05012408, NCI-6996, 6996, NCT00134069, UCHSC-07-0571
23.	Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-Advanced Rectal Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: COR0001, 95054, COR0001, NCT00226941, NCT00226941
24.	Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: HOG LUN04-79, NCT00216203
25.	SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: 05-439, NCT00361244